Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors. In nonsquamo…
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients.
Old cancer drugs failed, but one new drug saves high-risk kidney patients today.
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Preclinical report suggests combined ARSB and pembrolizumab inhibits melanoma progression in mice
Mouse model shows combined ARSB and pembrolizumab slows melanoma growth
This preclinical report evaluates the combination of recombinant human Arylsulfatase B (ARB) and pembrolizumab in a B16F10 syngeneic mouse m…
In a lab mouse model, combining a specific enzyme with pembrolizumab slowed tumor growth and improved survival, offering early clues for fut…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma
New Scan Shows Exactly Which Immune Cells Fight Cancer
This review discusses a proof-of-concept study examining PD1/PDL1 spatial interactions in tumor samples from patients with metastatic urothe…
This new method lets doctors see exactly which immune cells are actually fighting the tumor, not just hanging out nearby.
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis.
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Pembrolizumab plus chemotherapy improved event-free survival in Japanese patients with untreated locally advanced triple-negative breast cancer
An Immune-Boosting Drug Raises Breast Cancer Survival Odds Before Surgery
This phase 3 randomized controlled trial subgroup analysis included 76 Japanese patients with untreated locally advanced triple-negative bre…
Japanese women with aggressive early breast cancer saw higher 5-year survival odds when an immune-boosting drug was added to chemotherapy be…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.